ABIOMED Inc. (ABMD)

359.24
2.80 0.78
NASDAQ : Health Technology
Prev Close 362.06
Open 361.77
Day Low/High 358.06 / 364.31
52 Wk Low/High 258.10 / 459.75
Volume 306.08K
Avg Volume 527.70K
Exchange NASDAQ
Shares Outstanding 45.09M
Market Cap 16.32B
EPS 2.50
P/E Ratio 75.27
Div & Yield N.A. (N.A)

Latest News

Chart of the Day: Abiomed

ABMD has planted a bottom.

Abiomed Third Quarter Fiscal 2019 Earnings And Conference Call Notification

Abiomed Third Quarter Fiscal 2019 Earnings And Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, January 31, 2019, the company will release financial results for the third quarter of fiscal 2019.

Abiomed To Present At The 37th Annual J.P. Morgan Healthcare Conference

Abiomed To Present At The 37th Annual J.P. Morgan Healthcare Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R.

Abiomed May Have Good Fundamentals but the Charts Show More Risk Ahead

Abiomed May Have Good Fundamentals but the Charts Show More Risk Ahead

In the daily bar chart of Abiomed we can see a number of bearish signals.

Hormel, Medtronic, Cisco and More: 'Mad Money' Lightning Round

Hormel, Medtronic, Cisco and More: 'Mad Money' Lightning Round

Jim Cramer weighs in on Hormel, Medtronic, Cisco and more.

The Fed Is Wrong: Cramer's 'Mad Money' Recap (Thursday 12/20/18)

The Fed Is Wrong: Cramer's 'Mad Money' Recap (Thursday 12/20/18)

Jim Cramer says the market pain will eventually end, once the Fed sees the error of its ways.

An Explanation Of Design And Results Of The STEMI Door-to-Unloading Safety And Feasibility Trial. (Graphic: Abiomed, Inc.)

An Explanation Of Design And Results Of The STEMI Door-to-Unloading Safety And Feasibility Trial. (Graphic: Abiomed, Inc.)

Abiomed (NASDAQ: ABMD) announces the results of the FDA STEMI Door-to-Unloading safety and feasibility randomized controlled trial, which show unloading the left ventricle with Impella CP ® for 30 minutes prior to reperfusion in patients presenting with...

Listen to the CEOs: Cramer's 'Mad Money' Recap (Tuesday 10/9/18)

Listen to the CEOs: Cramer's 'Mad Money' Recap (Tuesday 10/9/18)

Jim Cramer is concerned about risk, and the Fed. But, he says, you need to get in there and talk with the CEOs to get the real story about the economy.

Express Scripts, Lockheed Martin: 'Mad Money' Lightning Round

Express Scripts, Lockheed Martin: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Express Scripts, Lockheed Martin, Raytheon, Abiomed.

Abiomed Is Set for Big Gains Once It Breaks Out Above $460

Abiomed Is Set for Big Gains Once It Breaks Out Above $460

Let's check out the charts and indicators.

Another Day of Rotation, but of a Different Sort

Another Day of Rotation, but of a Different Sort

Big-cap FAANG names and Apple, in particular, were the beneficiaries.

Children's Place, Abiomed, Barrick Gold: 'Mad Money' Lightning Round

Children's Place, Abiomed, Barrick Gold: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Children's Place, Abiomed, Barrick Gold, Dynavax Technologies, Zebra Technologies, Chesapeake Energy.

Be Alert For Buying Opportunities: Cramer's 'Mad Money' Recap (Monday 7/16/18)

Be Alert For Buying Opportunities: Cramer's 'Mad Money' Recap (Monday 7/16/18)

Jim Cramer says this market is all about being opportunistic, about being willing to fight the tide.

10 Stocks That Investors Have Plowed Into This Year With Reckless Abandon

10 Stocks That Investors Have Plowed Into This Year With Reckless Abandon

Investors have fallen in love with 10 stocks this year despite their heady valuations. Talk about dangerous.

Automatic Data Processing, ADT, Abiomed: 'Mad Money' Lightning Round

Automatic Data Processing, ADT, Abiomed: 'Mad Money' Lightning Round

Jim Cramer weighs in on Automatic Data Processing, ADT, Discovery Communications, Abiomed, L Brands and more.

Stocks Defying Gravity: Cramer's 'Mad Money' Recap (Monday 6/11/18)

Stocks Defying Gravity: Cramer's 'Mad Money' Recap (Monday 6/11/18)

Markets look calm, but we're seeing some extraordinary breakouts, says Jim Cramer.

TheStreet Quant Rating: B- (Buy)